Similar news:
NEW YORK, NY, May 14, 2012 (MARKETWIRE around COMTEX) –
Biotech companies are looking to money in on a anti-obesity drug
market. The competition to move a initial weight-loss tablet to a marketplace is
heating adult as Arena Pharmaceuticals weight-loss tablet (Lorcaserin)
recently gained a subsidy of an FDA advisory panel. The Paragon
Report examines investing opportunities in a Biotech Industry and
provides equity investigate on Arena Pharmaceuticals, Inc.
/quotes/zigman/83618/quotes/nls/arna ARNA
+4.56%
and Orexigen Therapeutics, Inc.
/quotes/zigman/104573/quotes/nls/orex OREX
-0.20%
.
Access to a full association reports can be found at:
www.ParagonReport.com/ARNA
www.ParagonReport.com/OREX
Arena is now competing with Vivus and Orexigen Therapeutics to
bring a initial anti-obesity drug to a marketplace in scarcely 13 years.
All 3 of a companies’ drugs were formerly incited down by the
FDA. FDA advisers final week voted 18-4 that a advantages of Arena’s
Lorcaserin transcend a health risks.
According to new numbers from a Center for Disease Control and
Prevention over 78 million adults in a U.S. are obese. Obesity
significantly raises a risks for health problems such as diabetes,
heart attacks, and strokes. It is estimated that plumpness costs the
U.S. economy $147 billion a year in medicals costs and lost
productivity.
Paragon Report releases unchanging marketplace updates on a Biotech
Industry so investors can stay forward of a throng and make a best
investment decisions to maximize their returns. Take a few mins to
register with us giveaway at
www.ParagonReport.com and get exclusive
access to a countless batch reports and attention newsletters.
Arena is a clinical-stage biopharmaceutical association focused on
discovering, building and commercializing verbal drugs that aim G
protein-coupled receptors, an critical category of certified drug
targets, in 4 vital healing areas: cardiovascular, central
nervous system, inflammatory and metabolic diseases. The FDA is
scheduled to confirm on Arena Pharmaceuticals’ anti-obesity drug,
Lorcaserin by Jun 27.
Orexigen Therapeutics, a biopharmaceutical association focused on the
treatment of obesity, recently announced financial formula for the
first entertain of 2012. For a 3 months finished Mar 31, 2012,
Orexigen reported a net detriment of $10.4 million compared to a net loss
of $11.6 million for a initial entertain of 2011. Orexigen’s
anti-obesity drug, Contrave, was deserted by a FDA during a start of
2011. The association reported in Feb that they have perceived a
Special Protocol Assessment (SPA) from a FDA.
Paragon Report provides Market Research focused on equities that
offer expansion opportunities, value, and clever intensity return. We
strive to yield a many present marketplace activities. We
constantly emanate investigate reports and newsletters for a members.
The Paragon Report has not been compensated by any of the
above-mentioned companies. We act as eccentric investigate portal and
are wakeful that all investment entails fundamental risks. Please perspective the
full disclaimer at:
www.ParagonReport.com/disclaimer
SOURCE: Paragon Financial Limited
Copyright 2012 Marketwire, Inc., All rights reserved.
/quotes/zigman/83618/quotes/nls/arna
![]()
Add to portfolio
ARNA

![]()
/quotes/zigman/104573/quotes/nls/orex
![]()
Add to portfolio
OREX

![]()



By James Brumley







